Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma

Multiple myeloma (MM) is an incurable B-cell malignancy characterised by uncontrolled growth and accumulation of malignant plasma cells in the bone marrow. Aberrant expression of CD56 in patients with MM is thought to contribute to a worsened disease course and metastasis. We therefore investigated the regulation of the CD56 promoter in relation to typical clinical factors. We used qPCR and FACS to measure the expression levels of CD56, and potential regulatory factors in patients with MM and related these with MM progression/prognosis. The transcription factors BTBD3, Pax5, RUNX1 and MMSET were positively associated with CD56 expression, as was CYCLIN D1, which is involved in disease progression, anti-apoptosis and proliferation. RUNX1 was negatively associated with the survival of stem-cell transplanted patients. Our findings propose four potential activators of the CD56 promoter and for CD56 to be involved in proliferation and anti-apoptosis, leading to disease progression in MM.

[1]  M. Terol,et al.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Licht,et al.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. , 2008, Blood.

[3]  Barbara Kruk,et al.  Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma , 2008, Leukemia & lymphoma.

[4]  D. Hose,et al.  Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14) , 2007, Bone Marrow Transplantation.

[5]  H. Müller-Hermelink,et al.  Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. , 2007, Blood.

[6]  A. Rustgi,et al.  Cyclin D1 Induction through IκB Kinase β/Nuclear Factor-κB Pathway Is Responsible for Arsenite-Induced Increased Cell Cycle G1-S Phase Transition in Human Keratinocytes , 2005 .

[7]  S. Bicciato,et al.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[9]  R. Mann,et al.  The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor , 2005, Development.

[10]  Hong Chang,et al.  The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system , 2005, British journal of haematology.

[11]  Y. Kaneko,et al.  MYND‐less splice variants of AML1–MTG8 (RUNX1–CBFA2T1) are expressed in leukemia with t(8;21) , 2005, Genes, chromosomes & cancer.

[12]  D. Christiansen,et al.  Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML , 2005, Leukemia.

[13]  F. Zhan,et al.  Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray , 2004, Modern Pathology.

[14]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[15]  J. Downing,et al.  Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. , 2004, Blood.

[16]  A. Takeshita,et al.  Prognostic Significance of Surface Markers Expressed in Multiple Myeloma: CD56 and Other Antigens , 2004, Leukemia & lymphoma.

[17]  H. Johnsen,et al.  Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities , 2003, British journal of haematology.

[18]  M. Baccarani,et al.  Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. , 2003, Blood.

[19]  N. Callander,et al.  AML-1A and AML-1B regulation of MIP-1α expression in multiple myeloma , 2003 .

[20]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[21]  H. Johnsen,et al.  C-MAF Oncogene Dysregulation in Multiple Myeloma: Frequency and Biological Relevance , 2003, Leukemia & lymphoma.

[22]  M. Lacy,et al.  Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. , 2002, Blood.

[23]  R. Ohno,et al.  Clinicopathological and prognostic characteristics of CD56‐negative multiple myeloma , 2002, British journal of haematology.

[24]  H. Johnsen,et al.  FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance , 2002, British journal of haematology.

[25]  A. Friedman,et al.  AML1 stimulates G1 to S progression via its transactivation domain , 2002, Oncogene.

[26]  S. Ely,et al.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. , 2002, The American journal of pathology.

[27]  T. Rasmussen,et al.  Differential expression of CD56 and CD44 in the evolution 
of extramedullary myeloma , 2002, British journal of haematology.

[28]  H. Johnsen,et al.  Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma , 2001, European journal of haematology.

[29]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[30]  H. Johnsen,et al.  Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single‐cell and real‐time RT‐PCR assays , 1999, British journal of haematology.

[31]  S. Barrans,et al.  Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.

[32]  R. Bataille,et al.  The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma , 1998, Leukemia.

[33]  G. Morgan,et al.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.

[34]  G. Edelman,et al.  A binding site for Pax proteins regulates expression of the gene for the neural cell adhesion molecule in the embryonic spinal cord. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Asaoku,et al.  Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.

[36]  H. F. Barker,et al.  Expression of adhesion molecules LFA‐3 and N‐CAM on normal and malignant human plasma cells , 1992, British journal of haematology.

[37]  A T Look,et al.  Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. , 1992, Genomics.

[38]  P. Lacor,et al.  Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells , 1991, British journal of haematology.

[39]  J. Drach,et al.  Expression of the neural cell adhesion molecule (CD56) by human myeloma cells , 1991, Clinical and experimental immunology.

[40]  M. Mattei,et al.  Localization of the human NCAM gene to band q23 of chromosome 11: the third gene coding for a cell interaction molecule mapped to the distal portion of the long arm of chromosome 11 , 1986, The Journal of cell biology.

[41]  N. Callander,et al.  AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. , 2003, Blood.

[42]  Stephen L. Nutt,et al.  Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 , 1999, Nature.

[43]  B. Camp,et al.  Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines , 1998, Leukemia.

[44]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.